StockNews.com Initiates Coverage on Enzo Biochem (NYSE:ENZ)

StockNews.com initiated coverage on shares of Enzo Biochem (NYSE:ENZ) in a report issued on Saturday. The brokerage issued a hold rating on the medical research company’s stock.

Enzo Biochem Stock Down 0.9 %

ENZ stock opened at $1.11 on Friday. Enzo Biochem has a 12 month low of $0.99 and a 12 month high of $1.50. The firm’s fifty day simple moving average is $1.12 and its 200-day simple moving average is $1.13.

Hedge Funds Weigh In On Enzo Biochem

Institutional investors have recently modified their holdings of the stock. Wittenberg Investment Management Inc. acquired a new stake in Enzo Biochem during the fourth quarter worth about $95,000. Renaissance Technologies LLC boosted its position in Enzo Biochem by 2.6% in the 2nd quarter. Renaissance Technologies LLC now owns 2,499,546 shares of the medical research company’s stock worth $2,725,000 after purchasing an additional 64,417 shares in the last quarter. Finally, XTX Topco Ltd grew its stake in shares of Enzo Biochem by 94.5% during the 2nd quarter. XTX Topco Ltd now owns 28,262 shares of the medical research company’s stock worth $31,000 after purchasing an additional 13,735 shares during the period. Hedge funds and other institutional investors own 36.90% of the company’s stock.

About Enzo Biochem

Enzo Biochem, Inc develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis.